newsfilter
← Latest News
GlobeNewswire·

Quoin Pharmaceuticals Receives FDA IND Clearance to Initiate Phase 2 Study of QRX003 in Peeling Skin Syndrome

Quoin Expects to Initiate Phase 2 Study in 2H 2026, Study Plans to Enroll 6-8 Pediatric and Adult Patients in the U.S. and EuropeFDA Expressed No Safety Concerns Over Study Design and Duration of DosingFirst-Ever Formal